| Julie Rumbach, | |
|
198 Emily Dr, Clarksburg, WV 26301-5501 | |
| (304) 623-1491 | |
| (304) 623-1479 |
| Full Name | Julie Rumbach |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 198 Emily Dr, Clarksburg, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144522921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5881 (West Virginia) | Primary |
| 183500000X | Pharmacist | 03228431 (Ohio) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Julie Rumbach, 198 Emily Dr, Clarksburg, WV 26301-5501 Ph: () - | Julie Rumbach, 198 Emily Dr, Clarksburg, WV 26301-5501 Ph: (304) 623-1491 |
News Archive
Merge Healthcare Incorporated today announced its pending $6.05 cash per share offer for AMICAS, Inc.. Merge's proposal, for an aggregate of $248 million, represents a 13% premium to the previously-announced offer for AMICAS from a newly-formed affiliate of Thoma Bravo, LLC for $5.35 cash per share. Merge's current offer follows its offer of $6.00 cash per share that was made during the "go-shop" period contemplated by AMICAS' merger agreement with Thoma Bravo.
Researchers at the European Congress of Osteoporosis & Osteoarthritis in Bordeaux have presented new data * which shows that the economic burden of fragility fractures in the 27 member states of the European Union far exceeds previous estimates, with hip fractures accounting for around 55% of costs.
To highlight Pain Awareness Month in September, The Gerontological Society of America (GSA) - the nation's largest interdisciplinary organization devoted to the field of aging - is announcing two forthcoming publications focused on pain relief and medication for seniors.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 5 days ago
Jordan Burnette, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Clarksburg, WV 26301 Phone: 304-623-3461 | |
Cameron Allen Shrout, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 Emily Dr, Clarksburg, WV 26301 Phone: 304-918-6056 | |
Dr. Sydney Adrienna Bongiorni, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Drive, Clarksburg, WV 26301 Phone: 304-623-3461 | |
Dr. Kiersten Parsons, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Drive, Clarksburg, WV 26301 Phone: 304-623-3461 | |
Dr. Elizabeth Anne Means, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 198 Emily Dr, Clarksburg, WV 26301 Phone: 304-623-1482 Fax: 304-623-1112 | |
Jeanne Fields, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Med Center Dr, Clarksburg, WV 26301 Phone: 304-623-3461 | |
Sydnee Hewitt, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 198 Emily Dr, Clarksburg, WV 26301 Phone: 304-623-1482 Fax: 304-623-1112 |